Curevac Efficacy Covid. After its first-generation COVID-19 vaccine posted efficacy of just 48 in a late-stage trial CureVac is scaling back its manufacturing ambitions in Europe. CureVac has withdrawn its application to the European.
-CureVac NV said on Tuesday it will give up on its first-generation COVID -19 vaccine candidate and instead focus on. Germanys CureVac ditches first-generation Covid-19 jab CureVac blamed the disappointing outcome on the many coronavirus strains circulating by then and. German company CureVacs coronavirus vaccine is far less effective than other jabs already in use the firm said Wednesday.
CureVac in ongoing dialogue with EMA.
CureVac in collaboration with London-based GlaxoSmithKline also has a second-generation COVID-19 vaccine in the works that like its predecessor uses. Tuesday the German biotech said it. Bloomberg -- CureVac NV lost more than half its value after a preliminary analysis of a large study found its Covid-19 vaccine fell short of the high efficacy. CureVac in ongoing dialogue with EMA.
